Sabitlenmiş Tweet
Finally, $NANOX officially announced its offline participation in #RSNA.
It has been a long time since I decided to invest in $NNOX.
The reason why I chose it as a retirement item is because the founder suddenly died of liver cancer amid suspicions of scams due to numerous bad reviews, malicious criticism, and responsibility that was not shown in time,,,
It is also because I visited Yongin Fab twice in 2022 and 2023 and confirmed the actual operation of the cold cathode, but it is also because I recognized the reality that many people who were fighting for their lives during the pandemic and unfortunately passed away, and many people who are still suffering from aftereffects are being bombarded with excessive radiation CT, but there is no proper solution, and they are continuously being attacked by radiation even at a level where they cannot tell whether it is a disease or a medicine, and are undergoing in-depth diagnosis.
#Nanox's next version Arc-X is without a doubt the first step to realize the grand ambition, but the management should report a thousand times more honestly than the founder, and should not repeat the incident of replacing the nonsensical staff who opportunistically talk nonsense and deceiving investors with unmaintainable timelines.
If cost-effective, affordable low-dose lung diagnosis is made, a realistic foundation for creating a public health market will be newly formed, and all the health institutions in the world will have to think together and implement a policy to encourage early diagnosis and progress monitoring solutions for chronic diseases nationwide.
$Nanox's only competitive edge is the real end-user, medical finance and insurance (Reimbursement) reduction, which is a breakthrough, and there are great expectations.
With the confidence that it will become a national and global low-power safety solution for excessive medical expenses, we hope that this first RSNA participation will change the image to a new approach of low-dose, low-power, low-price, but with the highest quality service.
picture source: Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection
English
